Novavax and its partner SK bioscience have obtained a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), to be used in adolescents of the age 12 to 17 years.

The vaccine is indicated for active immunisation for the prevention of Covid-19 in people of this age group.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

KMFDS granted the approval based on findings from a paediatric expansion of Phase III PREVENT-19 clinical trial underway to analyse the safety, immunogenicity and efficacy of the vaccine. 

It enrolled 2,247 adolescents across 73 US sites.

According to the trial findings, the vaccine met the primary immunogenicity endpoint and offered an overall clinical efficacy of 80% when the Delta variant of the SARS-CoV-2 virus was predominant in the country.

Initial safety results showed that Nuvaxovid was generally well-tolerated. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following the initial two-dose regimen, local and systemic reactogenicity was found to be generally reduced than or in line with adults.

Tenderness/pain at the site of injection, headache, fatigue, myalgia and malaise was seen to be the most common adverse reactions in the trial. 

Furthermore, no new safety signal was reported through the trial’s placebo-controlled portion.

In January, the vaccine obtained KMFDS approval for use in adults aged 18 years and above.

SK bioscience and Novavax have a licensing agreement in place in Korea, with the former producing drug substance and drug product of the vaccine for use in the region.

The vaccine is currently authorised for use in 12 to 17-year-old people in the EU, India, Australia, Thailand and Japan and is also being reviewed in various other markets. 

Novavax president and CEO Stanley Erck said: “The approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option. 

“We are pleased to collaborate with SK bioscience to offer our vaccine to adolescents aged 12 through 17 in South Korea.”